Panagiotis Mavros

Chief Scientific Officer

KREDHERA

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Panagiotis Mavros is the Chief Scientific Officer at KREDHERA in the United States. His research focuses on innovative analytic methodologies and clinical impact studies, particularly in the context of schizophrenia treatment and multiple myeloma management. Recent publications include works on long-acting injectable antipsychotics and treatment advancements for high-risk newly diagnosed patients.

Articles (5)

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (1)

Jessica Young

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Panagiotis Mavros

Research Interests

Explore related searches

Contact this professor

About

Articles (5)

Alternative analytic and matching approaches for the prevalent new‐user design: A simulation study

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia.

Correction to: Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.

Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.

Collaborators (1)

Jessica Young

Make your next move.